The greatest risk of all-grade PAEs in patients with head and neck cancer was linked to anti-PD1 plus targeted therapy drug, which had significant differences with the other interventions except for anti-PDL1 plus chemotherapy. This evidence concerns the gene PDCD1 and head and neck cancer.